^
    Back
    Association details:
    Biomarker:KRAS exon 2 mutation
    Cancer:Pancreatic Cancer
    Drug:erlotinib (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Mol Cancer Ther
    Title:

    Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy

    Excerpt:
    Patients with KRAS mutations showed a worse response (11.3%) than those with wild-type KRAS (26.2%) and poor survival (mutant KRAS, 5.8 months vs. wild-type KRAS, 8.0 months; P = 0.001).
    Secondary therapy:
    gemcitabine
    DOI:
    10.1158/1535-7163.MCT-11-0269